How much does dasatinib cost per month?

Dasatinib is a highly effective anti-tumor drug, mainly used to treat patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) who are resistant or intolerant to imatinib mesylate. CML is a clonal disease originating from bone marrow hematopoietic stem cells and is characterized by the BCR-ABL fusion gene formed by translocation of chromosome 9 or 22, resulting in uncontrolled cell proliferation. Dasatinib inhibits the activity of ABL kinase and blocks the abnormal function of BCR-ABL protein, thereby inhibiting the proliferation and survival of leukemia cells and effectively controlling the disease.

The dosage of dasatinib varies according to the patient's disease stage and individual response. For patients with Ph+ chronic phase CML, the recommended starting dose is 100 mg, taken orally once daily. The time of administration should be consistent, whether in the morning or evening. If patients fail to achieve hematological or cytogenetic remission at the recommended starting dose, the dose may be increased to 140 mg once daily. For CML patients in the Ph+ accelerated phase and blast phase (including blast myeloblastosis and blast crisis), the recommended starting dose is 70 mg twice a day, taken orally in the morning and evening. If the effect is not good, the dose can be adjusted to 90 mg twice daily.

The administration of dasatinib is not affected by food and can be taken with or on an empty stomach. Tablets should be swallowed whole and not crushed or cut. During the treatment process, the doctor will adjust the dosage according to the patient's response and tolerance to achieve the best therapeutic effect.

It is important to note that dasatinib has some bone marrow suppressive effects and may lower blood cell counts, leading to bleeding problems, infection, or anemia. Therefore, while taking dasatinib, patients should regularly monitor complete blood cell counts and international normalized ratios, and follow the doctor's instructions for blood, heart function, and pulmonary function tests. For patients with a history of bleeding tendency or coagulation dysfunction, this product should be used with caution to avoid aggravating the risk of bleeding.

Currently, dasatinib has been launched in the country and is included in Class B medical insurance. There are two domestically produced versions: original research and domestically produced generic versions. The original version 50mg*60 tablets costs about 9,000 yuan after medical insurance reimbursement, and the generic version 50mg*7 tablets costs about 500 yuan. At the same time, various imitation versions have also been launched overseas, such as India and Bangladesh. 50mg*60 tablets are priced at 600-1,000 yuan, and the price/performance ratio is better than the domestic version.

Based on usage and dosage, for the treatment of patients with Ph+ chronic phase CML, the domestically marketed original version of dasatinib costs about 9,000 yuan a month, and the domestically marketed generic version costs about 4,000 yuan. In contrast, the overseas preventive version costs only 600-1,000 yuan a month. Patients can choose products that suit them based on their actual conditions.

In short, dasatinib, as an important anti-tumor drug, provides a new treatment option for CML patients who are resistant or intolerant to imatinib mesylate. However, its usage and dosage must be strictly followed as prescribed by the doctor, and adverse reactions must be monitored to ensure therapeutic efficacy and patient safety.